Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.53 |
| ▸ | CDK2 | P24941 | 18/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 17/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19112204 | 0.79 | CDK2 (0.43) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL19111920 | 0.77 | CDK1 (0.46) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL23992724 | 0.76 | CDK1 (0.57) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL22651959 | 0.76 | CDK1 (0.57) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL19112198 | 0.76 | CDK1 (0.57) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL30822737 | 0.74 | CLK1 (0.58) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL6751476 | 0.70 | CCNE2 (0.48) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL6751475 | 0.70 | CCNE2 (0.48) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL30822749 | 0.69 | CLK1 (0.67) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL6824059 | 0.68 | FLT3 (0.58) | CCNE1CDK2CCNE2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| WO-2021214315-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| EP-2664619-B1 | Purine derivatives as tools for screening anti-Alzheimer compounds | MANROS THERAPEUTICS (FR) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | CCNE1 2397/4885CDK2 1842/4885CCNE2 3110/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | CCNE1 4732/4885CDK2 3765/4885CCNE2 4742/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | CCNE1 4732/4885CDK2 3765/4885CCNE2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.